One series of studies produced evidence that selegiline binds to GAPDH and prevents the nuclear translocation of this enzyme (Carlile et al., 2000), however the tricyclic selegiline derivative CGP3466 (Omigapil), which does not inhibit MAO, binds GAPDH and prevents its nuclear translocation, possesses anti-apoptotic activity in vitro and in vivo (Waldmeier et al., 2000) but was not effective in clinical trials for PD and ALS. Here, GAPDH is linked to Parkinson disease.